BRD7

Across TCGA pan-cancer cohorts, BRD7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BRD7 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher BRD7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BRD7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, LIHC, and UCEC are the cancer types where BRD7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
LIHC	DFS	Median	All	0.300	0.557	.027	9	view →
UCEC	DFS	Median	All	0.959	0.626	.023	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BRD7–MESO (OS)

Open the MESO breakdown →